Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Closes Collaboration with Biogen Idec After Receiving Second and Third Milestone Payments

NEW YORK, Aug. 13 (GenomeWeb News) - Drug discovery company Syrrx Inc. announced today that it has closed its collaboration with Biogen Idec after receiving the second and third success-based milestone payments from the company.


The company received its first success-based payment from Biogen Idec on  May 27 . According to an agreement signed on Dec. 16, 2003, all success-based payments have now been completed.


Financial terms of the payments were not disclosed.


Syrrx said its collaboration with Biogen Idec allowed the company to apply its expertise in high-throughput protein crystallization to multiple drug targets that Biogen Idec has developed.


Stephen Kaldor, Syrrx's president and chief scientific officer, said that collaboration between the two companies demonstrated that Syrrx can rapidly generate valuable structural data on challenging drug discovery targets.


"We look forward to exploring opportunities to expand our relationship with Biogen Idec in the future," Kaldor said.


The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.